RegeneRx公司今天宣布其治疗跟踪组对69名病人已经完成RGN-259干眼症治疗的第二期临床试验。这比试验条款中规定的可供评估的病人数目还多5个。在所有的研究数据完成质量控制过程和数据锁定后,将进行统计分析。按实验日程安排重要的结果将会在十月末报告。这次双盲的、安慰剂对照的临床实验将评估RGN-259,一种公司专有的...
RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair and regeneration), announced that the results of the initial randomized, double-masked, placebo-controlled, phase 3 clinical...
ReGenTree, LLC, a joint venture between GtreeBNT and RegeneRx Biopharmaceuticals, announced that it has executed an agreement with Ora, Inc., located in Andover, Massachusetts, for the initiation of ARISE-3 to study the company's new drug RGN-259 for the treatment of dry eye syndrome. ARIS...
Neil Lyons, chief financial officer and treasurer of RegeneRx Biopharmaceuticals, Inc., is presented. He described the nature of the company. RegeneRx Biopharmaceuticals is involved in the development of a molecule called thymosin beta 4. He explained the agenda of the company over the next 12 ...
J. Finkelstein, president and chief executive officer of RegeneRx Biopharmaceuticals Inc. He provides a brief historical sketch of the company and a picture of the company as of February 2006. He reveals the company's agenda for the next 12 months. He describes the shareholder base and ...
RegeneRx Biopharmaceuticals, Inc. announced that it completed enrollment of its first of four ongoing Phase II clinical trials. The trial is a double-blind, placebo-controlled, dose-escalating cl ...placebocontrolleddoseescalating cl